The present invention discloses and claims compounds of formula (I) ##STR00001## as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
Claims What is claimed is: 1. A compound of formula (I) ##STR00012## wherein: R.sub.1 is H or C.sub.1-6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is H, C.sub.1-6alkyl, C.sub.1-6alkoxy, CF.sub.3, halogen, S--C.sub.1-6alkyl, --SH, --NH.sub.2 or NR.sub.5R.sub.6; R.sub.5 is H or C.sub.1-6alkyl; R.sub.6 is H or C.sub.1-6alkyl. 2. The compound according to claim 1 wherein R.sub.1 is H or C.sub.1-6alkyl, R.sub.5 is H, R.sub.6 is H or C.sub.1-6alkyl, and R.sub.3 is aryl. 3. The compound according to claim 2 selected from the group consisting of:1-methyl-3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide, 1-methyl-3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, and 3-phenylsulfanyl-1-propyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide. 4. The compound according to claim 1 wherein R.sub.1, R.sub.4 and R.sub.5 are each H, R.sub.3 is aryl and R.sub.6 is C.sub.1-6alkyl. 5. The compound according to claim 4 selected from the group consisting of: 3-(3-trifluoromethyoxyphenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carb- oxylic acid methylamide, 3-(3-chlorophenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide, 3-(3-fluorophenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide, and 3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid methylamide. 6. The compound according to claim 1 wherein R.sub.1, R.sub.4, R.sub.5 and R.sub.6 is each H and R.sub.3 is heterocycle. 7. The compound according to claim 6 is selected from the group consisting of: 3-(quinolin-8-ylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(pyridin-2-sulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(pyridin-4-sulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, and 3-(thiophen-2-ylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide. 8. The compound according to claim 6 wherein R.sub.1, R.sub.5 and R.sub.6 are each H and R.sub.3 is aryl. 9. The compound according to claim 1 selected from the group consisting of: 3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-bromophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(2-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(4-chlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(2,4-dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxy- lic acid amide, 3-(2-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(2,3-dichlorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxy- lic acid amide, 3-(2-trifluormethylphenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-trifluoromethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxyl- ic acid amide, 3-(2-aminophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(2,5-dichloro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carbox- ylic acid amide, 3-(2-methoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-methoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxyli- c acid amide, 3-(3-amino-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(4-nitro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-nitro-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-o-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-p-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3,5-dimethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carbox- ylic acid amide, 3-m-tolylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(2-ethyl-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 3-(3-trifluoromethoxy-phenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-- carboxylic acid, amide, 3-(3-fluoro-phenylsulfanyl)-5-methoxy-1H-pyrrolo[3,2-b]pyridine-2-carboxy- lic acid amide, and 3-(3-methoxy-phenylsulfanyl)-5-methoxy-1H-pyrrolo[3,2-b]pyridine-2-carbox- ylic acid amide. 10. A pharmaceutical composition comprising one or more pharmaceutical carriers and a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of formula (I): ##STR00013## wherein: R.sub.1 is H or C.sub.1-6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is H, C.sub.1-6alkyl, C.sub.2-6-alkenyl, C.sub.2-6-alkynyl, C.sub.1-6alkoxy, CF.sub.3, halogen, SH, S--C.sub.1-6alkyl, NO.sub.2, NH.sub.2 or NR.sub.5R.sub.6; R.sub.5 is H or C.sub.1-6alkyl; R.sub.6 is H or C.sub.1-6alkyl. 11. The pharmaceutical composition of claim 10 wherein said pharmaceutical carrier is selected from the group consisting of diluents, binders, solvents, disintegrating agents, lubricants, sweetening agents, bulking agents, permeation enhancers, and solvents. 